product name Cyproheptadine HCl
Description: Cyproheptadine HCl is a hydrochloride salt form of cyproheptadine which is a histamine receptor antagonist. In addition, Cyproheptadine is also a serotonin as well as an antimuscarinic reagent. It is used to treat for postgastrectomy-dumping syndrome, pruritic dermatoses, migraine, anorexia, and pituitary-dependent Cushings syndrome. As a 5-HT2A receptor antagonist, cyproheptadine is found to reverse serotonin-enhanced ADP-induced platelet aggregation in vitro and ex vivo suggesting its antiplatelet and thromboprotective effects
References: J Anal Toxicol. 1998 Jan-Feb;22(1):72-4; PLoS One. 2014 Jan 23;9(1):e87026.
323.86
Formula
C21H21N.HCl
CAS No.
969-33-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 65 mg/mL (200.7 mM)
Water: <1 mg/mL
Ethanol: 20 mg/mL (61.8 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19428027
| In Vitro |
In vitro activity: Cyproheptadine is a serotonin and histamine antagonist as well as an antimuscarinic reagent. It is used to treat for postgastrectomy-dumping syndrome, pruritic dermatoses, migraine, anorexia, and pituitary-dependent Cushings syndrome. The major urinary product of cyproheptadine is cyproheptadine glucuronide, a quaternary ammonium compound. Cyproheptadine has some side effects including sedation, drowsiness, hypotension, tachycardia and blood dyscrasias. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | a 5-HT2A receptor antagonist, cyproheptadine is found to reverse serotonin-enhanced ADP-induced platelet aggregation in vitro and ex vivo suggesting its antiplatelet and thromboprotective effects. |
| Animal model | |
| Formulation & Dosage | |
| References | J Anal Toxicol. 1998 Jan-Feb;22(1):72-4; PLoS One. 2014 Jan 23;9(1):e87026. |
